AR059625A1 - Aminoindanos propargilados, procesos para su preparacion, y usos de los mismos - Google Patents

Aminoindanos propargilados, procesos para su preparacion, y usos de los mismos

Info

Publication number
AR059625A1
AR059625A1 ARP070100776A ARP070100776A AR059625A1 AR 059625 A1 AR059625 A1 AR 059625A1 AR P070100776 A ARP070100776 A AR P070100776A AR P070100776 A ARP070100776 A AR P070100776A AR 059625 A1 AR059625 A1 AR 059625A1
Authority
AR
Argentina
Prior art keywords
propargiled
aminoindans
processes
preparation
same
Prior art date
Application number
ARP070100776A
Other languages
English (en)
Inventor
Istvan Miskolczi
Dalia Pinkert
Hugo Gottlieb
Yaacov Herzig
Victor Piryatinsky
David Lerner
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR059625A1 publication Critical patent/AR059625A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/48—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos con la estructura: (1) donde R1 es metilo y R2 es H; o R1 es etilo y R2 es hidroximetilo; R3 es H o propargilo; y R4 es ya sea H o 1-butiloxicarbonilo; o un enantiomero o una sal del mismo aceptable para uso farmacéutico. También se provee el uso de una cantidad efectiva para uso terapéutico de dichos compuestos para tratar a un sujeto que sufre un trastorno psiquiátrico, enfermedad de Parkinson. enfermedad de Alzheimer, demencia, o un trastorno neurologico.
ARP070100776A 2006-02-24 2007-02-23 Aminoindanos propargilados, procesos para su preparacion, y usos de los mismos AR059625A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77638606P 2006-02-24 2006-02-24

Publications (1)

Publication Number Publication Date
AR059625A1 true AR059625A1 (es) 2008-04-16

Family

ID=38459533

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100776A AR059625A1 (es) 2006-02-24 2007-02-23 Aminoindanos propargilados, procesos para su preparacion, y usos de los mismos

Country Status (4)

Country Link
US (2) US7625946B2 (es)
AR (1) AR059625A1 (es)
TW (1) TW200744576A (es)
WO (1) WO2007100583A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006216509B8 (en) 2005-02-24 2012-11-01 Technion Research And Development Foundation Ltd Formulations of ladostigil tartrate
US20070135518A1 (en) * 2005-12-09 2007-06-14 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
AU2006326642B2 (en) * 2005-12-09 2012-05-03 Technion Research And Development Foundation Ltd. Use of low-dose ladostigil for neuroprotection
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
WO2007126898A2 (en) * 2006-03-31 2007-11-08 Teva Pharmaceutical Industries, Ltd. Use of ladostigil for the treatment of schizophrenia
US9114135B2 (en) 2010-08-24 2015-08-25 Sgc Pharma Inc. Salt compound
WO2012059920A1 (en) * 2010-11-02 2012-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Ladostigil dosage regime
AU2013217176B2 (en) 2012-02-12 2017-10-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Ladostigil therapy for immunomodulation
CN113993584A (zh) * 2019-05-28 2022-01-28 耶路撒冷希伯来大学伊森姆研究发展有限公司 用于递送拉多替吉的组合物

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3123642A (en) * 1964-03-03 Indanyl and tetrahydronaphthyl
US2916490A (en) * 1959-12-08 Ocjhs
US2982783A (en) * 1961-05-02 Amevoevdanes
US3201470A (en) * 1965-08-17 Chsx c cech
SE371190B (es) * 1972-03-24 1974-11-11 Kabi Ab
US2573645A (en) * 1949-05-25 1951-10-30 Smith Kline French Lab N-hydroxyethyl aminoindanes
GB852735A (en) 1956-04-13 1960-11-02 Schering Ag Manufacture of 1-aminoindanes
US3178478A (en) * 1961-02-13 1965-04-13 Ciba Geigy Corp 2-amino-5-halo-indanes
US3060091A (en) * 1961-02-13 1962-10-23 Ciba Geigy Corp Analgesic composition consisting of morphines and amino-indanes
US3253037A (en) * 1962-06-19 1966-05-24 Ciba Geigy Corp N-2-alkynyl-amino-benzocylo-alkanes
US3709996A (en) * 1963-08-02 1973-01-09 Aspro Nicholas Ltd Pharmaceutical compositions containing n-cyclopropyl-1-aminoindane compounds and adapted for administration to obtain inhibition of monoamine oxidase enzyme and process
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
NL6408165A (es) * 1964-07-17 1966-01-18
US3308157A (en) * 1964-08-07 1967-03-07 Colgate Palmolive Co N-(benzocyclobutene-1-loweralkyl)-carboxylic acid amides
US3637740A (en) * 1969-04-21 1972-01-25 Pfizer Aminobenzocycloalkane compounds
US3507962A (en) * 1969-05-09 1970-04-21 Thompson Chem Co Hayward Controlling leafminer insects with selected carbamate insecticides,including 3,5-dimethyl-4-dimethylamino-methyl phenyl-n-methylcarbamate
US3704323A (en) * 1969-12-23 1972-11-28 Squibb & Sons Inc Indane derivatives
NL7011683A (es) * 1970-08-07 1972-02-09
US3991207A (en) * 1971-03-18 1976-11-09 Pfizer Inc. Combination therapy for Parkinson's disease
US3751420A (en) * 1971-04-01 1973-08-07 Squibb & Sons Inc Monoolmonoene amines
BE786748A (fr) * 1971-07-26 1973-01-26 Basf Ag 1-aminomethyl-indanes-n-substitues
US3903297A (en) * 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US4029731A (en) * 1974-11-06 1977-06-14 Pfizer Inc. Aminophenyltetralin compounds
US4134997A (en) * 1977-03-01 1979-01-16 University Of Iowa Research Foundation Effect of an aminotetralin derivative on coronary blood flow in infarcted hearts
US4096173A (en) * 1977-03-28 1978-06-20 Eli Lilly And Company Chlorinated 1-aminoindane N-methyl transferase inhibitors
US4128666A (en) * 1977-08-18 1978-12-05 Smithkline Corporation 4 AND 5-Halo substituted 2-indanamine compounds
US4132737A (en) * 1978-02-27 1979-01-02 Eli Lilly And Company Trifluoromethyl substituted 1-aminoindanes
US5286747A (en) * 1981-05-08 1994-02-15 Per A. E. Carlsson 1-alkyl-2-aminotetralin derivatives
ES8602606A1 (es) * 1983-03-04 1985-12-01 Otsuka Pharma Co Ltd Derivados de indano y sus sales
US4529723A (en) * 1983-04-29 1985-07-16 William H. Rorer, Inc. Bicyclic benzenoid aminoalkylene ethers and thioethers, pharmaceutical compositions and use
JPS6169747A (ja) * 1984-08-31 1986-04-10 Otsuka Pharmaceut Co Ltd ２，３―ジヒドロ―１ｈ―インデン誘導体及びその製造法
US5242919A (en) * 1984-08-31 1993-09-07 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-1H-indene derivatives
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US4632939A (en) * 1985-03-15 1986-12-30 Eli Lilly And Company Anticonvulsant agents
US4833273A (en) * 1986-02-03 1989-05-23 Warner-Lambert Company Process for the resolution of 1-aminoindanes
EP0252290B1 (en) * 1986-06-10 1992-06-03 CHIESI FARMACEUTICI S.p.A. Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
US5153225A (en) * 1986-12-10 1992-10-06 Bayer Aktiengesellschaft Substituted basic 2-aminotetralin in pharmaceuticals
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
US5011995A (en) * 1987-07-28 1991-04-30 Ciba-Geigy Corporation Process for the preparation of optically active secondary amines
US4873241A (en) * 1988-10-31 1989-10-10 Fisons Corporation 2-amino-N-(2-phenylindan-2-yl)acetamides useful as anti-epileptics
US5225596A (en) 1989-01-09 1993-07-06 The Upjohn Company Halo substituted aminotetralins
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
JP2725378B2 (ja) 1989-05-29 1998-03-11 武田薬品工業株式会社 カルバミド酸エステル誘導体
IE902294A1 (en) 1989-07-06 1991-01-16 Abbott Lab Alkynyl amines that regulate cholinergic neurotransmission
US5118704A (en) * 1989-08-30 1992-06-02 Whitby Research, Inc. Substituted 2-aminotetralins useful as dopaminergics
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2654104B1 (fr) * 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
JPH03176457A (ja) * 1989-12-04 1991-07-31 Nippon Paint Co Ltd 新規プロパルギル化合物、その製法ならびに該化合物を含む被覆材
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
FR2662162B1 (fr) * 1990-05-18 1995-01-20 Adir Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
TW197435B (es) * 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
US5646181A (en) * 1992-07-02 1997-07-08 Research Foundation Of State University Of New York Method and compositions for treating impotence
DE69329067T2 (de) 1992-10-05 2001-05-10 Ube Industries, Ltd. Pyridmidin-derivate
US5350762A (en) 1993-03-08 1994-09-27 Hoechst-Roussel Pharmaceuticals Incorporated Tetrahydrocyclopent[B]indole methanamines and related compounds
EP0697894A4 (en) 1993-03-31 1996-05-01 Univ Pennsylvania DOPAMINE D-3 AND SEROTONIN (5-HT 1A) RECEPTOR LIGANDS AND IMAGING AGENTS
GB9315600D0 (en) 1993-07-28 1993-09-08 Smithkline Beecham Plc Compounds
EP0712387B1 (en) * 1993-08-06 1999-12-08 PHARMACIA & UPJOHN COMPANY 2-aminoindans as selective dopamine d3 ligands
US5516943A (en) * 1993-09-14 1996-05-14 Sepracor, Inc. Process for preparing cyclic CIS-1-amino-2-alkanols
US5401758A (en) * 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US5877218A (en) * 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
FR2717175B1 (fr) * 1994-03-11 1996-06-14 Adir Nouveaux composés alkylaminoindanes, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
IT1271679B (it) 1994-07-18 1997-06-04 Mediolanum Farmaceutici Srl Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
US5646188A (en) * 1995-07-05 1997-07-08 Teva Pharmaceutical Industries, Ltd. Polyamine derivatives of 1-aminoindan
DE19529604A1 (de) 1995-08-11 1997-02-13 Bayer Ag Endoparasitizide Mittel auf Basis von Didepsipeptiden, neue Didepsipeptide und ein Verfahren zu ihrer Herstellung
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE69725467T2 (de) 1996-12-18 2004-07-22 Teva Pharmaceutical Industries Ltd. Phenylethylamin-derivate
US6251938B1 (en) * 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
IL130528A (en) * 1996-12-18 2004-12-15 Teva Pharma Aminoindan derivatives, pharmaceutical compositions comprising them and uses thereof
EP1490324A4 (en) 2002-02-27 2007-10-10 Teva Pharma PROPARGYLAMINOINDANE DERIVATIVES AND PROPARGYLAMINOTETRALIN DERIVATIVES AS BRAIN-LIKE MAO INHIBITORS
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
JP2007537294A (ja) * 2004-05-14 2007-12-20 ザ・ジョンズ・ホプキンス・ユニバーシティー Ｇａｂａｂレセプターアンタゴニストとアセチルコリンエステラーゼインヒビターとの同時投与により認識機能を改善するための方法
JP4738019B2 (ja) * 2005-02-23 2011-08-03 任天堂株式会社 ゲームプログラム、ゲーム装置、ゲーム制御方法およびゲームシステム
AU2006216509B8 (en) 2005-02-24 2012-11-01 Technion Research And Development Foundation Ltd Formulations of ladostigil tartrate
JP2008531571A (ja) * 2005-02-24 2008-08-14 テバ ファーマシューティカル インダストリーズ リミティド 酒石酸ラドスチジルの結晶、その製造方法、および医薬組成物
US20060276537A1 (en) * 2005-06-01 2006-12-07 Tamar Goren Use of ladostigil for the treatment of multiple sclerosis
AU2006326642B2 (en) 2005-12-09 2012-05-03 Technion Research And Development Foundation Ltd. Use of low-dose ladostigil for neuroprotection
US20070135518A1 (en) * 2005-12-09 2007-06-14 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
WO2007126898A2 (en) * 2006-03-31 2007-11-08 Teva Pharmaceutical Industries, Ltd. Use of ladostigil for the treatment of schizophrenia

Also Published As

Publication number Publication date
WO2007100583A2 (en) 2007-09-07
US20070203232A1 (en) 2007-08-30
WO2007100583A3 (en) 2008-11-06
US7625946B2 (en) 2009-12-01
US8609719B2 (en) 2013-12-17
US20100093848A1 (en) 2010-04-15
TW200744576A (en) 2007-12-16

Similar Documents

Publication Publication Date Title
AR059625A1 (es) Aminoindanos propargilados, procesos para su preparacion, y usos de los mismos
CL2008002271A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida o su sal farmaceutica; proceso de preparacion; compuestos intermediarios; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar un trastorno del sistema nervioso central tal como alzheimer, demencia senil, parkinson.
UY28752A1 (es) Agentes terapeuticos
UY28374A1 (es) Agentes terapéuticos
CL2013001558A1 (es) El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
GT200800265A (es) Pirido (3,2-e)piracinas, su uso como inhibidores de fosfadiesterasa 10, y procesos para prepararlas.
ECSP088499A (es) Nuevos compuestos de 2-amino-imidazol-4-ona y su uso en la fabricación de un medicamento para uso en el tratamiento de alteración cognitiva, enfermedad de alzheimer, neurodegeneración y demencia
CL2011003302A1 (es) Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros.
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
UY28839A1 (es) Agentes terapeuticos
CU20130116A7 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
AR068510A1 (es) Derivados de 4-fenil-1h-piridin-2-ona - 1,3 disustituidos, composiciones farmaceuticas que los contienen y usos de los mismos para tratar o prevenir trastornos del sistema nervioso central.
UY30408A1 (es) Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
ECSP077275A (es) Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
UY28376A1 (es) Agentes terapéuticos
UY31554A1 (es) Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus
UY28144A1 (es) Agentes terapéuticos
EA200700909A1 (ru) Азаиндолкарбоксамиды
AR068045A1 (es) Derivados de catecolamina y prodrogas de los mismos
CR9721A (es) Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos
BR122018070508B8 (pt) derivados de arilamida triazol-substituída e seu uso
ECSP088366A (es) 1,2-diarilimidazoles para uso como moduladores de cb1
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
FB Suspension of granting procedure